Abstrakt
An ovarian cancer xMAPtechnology panel including leptin, prolactin, osteopontin, IGFII, MIF and CA125 was tested for multiplex measurement and compare to conventional serum markers in ovarian cancer patients and controls with benign ovarian disease.